Latest Ratios: P/E Ratio 0.2x · EV/EBITDA 4.1x · ROE 332.0%. (1999–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $162M | $292M | $9.5B | $62.5B | $25.3B | $106.3B | $159.1B | $247.5B | $251.7B | $281.4B | $70.3B |
| Enterprise Value | $470M | $600M | $10.9B | $63.9B | $26.6B | $107.6B | $160.6B | $249.1B | $253.2B | $283.1B | $72.1B |
| P/E Ratio → | 0.15 | 0.28 | — | — | — | 1581.31 | 2123.79 | 2068.96 | 1125.48 | 1718.30 | 1035.31 |
| P/S Ratio | 0.23 | 0.41 | 12.07 | 70.24 | 24.31 | 87.75 | 115.46 | 175.12 | 166.26 | 215.36 | 60.32 |
| P/B Ratio | 0.51 | 0.92 | — | — | — | — | — | — | — | — | — |
| P/FCF | — | — | — | — | 658.43 | 888.36 | 1860.82 | 1841.53 | 1011.87 | 1549.61 | 829.61 |
| P/OCF | — | — | — | 9345.63 | 329.82 | 675.70 | 1170.49 | 1357.04 | 851.62 | 1266.23 | 590.29 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.84 | 13.89 | 71.79 | 25.59 | 88.87 | 116.51 | 176.22 | 167.25 | 216.63 | 61.93 |
| EV / EBITDA | 4.12 | 5.26 | 93.63 | 814.22 | — | 439.07 | 601.74 | 747.91 | 584.79 | 889.77 | 284.66 |
| EV / EBIT | 10.12 | 0.52 | — | 2868.92 | — | 652.80 | 744.01 | 870.14 | 655.38 | 1097.89 | 362.01 |
| EV / FCF | — | — | — | — | 693.07 | 899.75 | 1877.78 | 1853.10 | 1017.94 | 1558.74 | 851.72 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 71.8% | 71.8% | 67.8% | 59.5% | 59.8% | 60.0% | 56.4% | 55.7% | 57.2% | 53.0% | 50.3% |
| Operating Margin | 6.5% | 6.5% | 10.0% | 2.9% | -27.3% | 16.2% | 15.7% | 20.4% | 25.7% | 20.5% | 17.2% |
| Net Profit Margin | 148.6% | 148.6% | -44.0% | -12.6% | -24.7% | 5.5% | 5.4% | 8.5% | 14.8% | 12.5% | 5.8% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 332.0% | 332.0% | — | — | — | — | — | — | — | — | — |
| ROA | 141.1% | 141.1% | -45.1% | -11.2% | -20.9% | 4.6% | 5.0% | 8.2% | 16.8% | 13.0% | 5.0% |
| ROIC | 7.4% | 7.4% | 12.6% | 3.1% | -27.5% | 16.3% | 18.3% | 27.4% | 43.2% | 30.5% | 21.9% |
| ROCE | 7.8% | 7.8% | 13.7% | 3.2% | -28.0% | 16.8% | 19.3% | 26.5% | 39.4% | 28.4% | 21.2% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.47 | 1.47 | — | — | — | — | — | — | — | — | — |
| Debt / EBITDA | 4.11 | 4.11 | 12.72 | 18.99 | — | 6.19 | 6.06 | 5.22 | 4.03 | 5.47 | 7.82 |
| Net Debt / Equity | — | 0.97 | — | — | — | — | — | — | — | — | — |
| Net Debt / EBITDA | 2.70 | 2.70 | 12.27 | 17.60 | — | 5.56 | 5.43 | 4.67 | 3.49 | 5.21 | 7.39 |
| Debt / FCF | — | — | — | — | 34.64 | 11.39 | 16.96 | 11.57 | 6.07 | 9.13 | 22.11 |
| Interest Coverage | 18.21 | 18.21 | -2.17 | 0.23 | -3.52 | 1.88 | 1.75 | 2.12 | 2.71 | 2.29 | 1.73 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.69 | 1.69 | 0.59 | 0.87 | 1.43 | 1.18 | 0.88 | 0.75 | 1.07 | 0.61 | 0.80 |
| Quick Ratio | 1.69 | 1.69 | 0.59 | 0.87 | 1.33 | 1.05 | 0.76 | 0.68 | 1.00 | 0.52 | 0.69 |
| Cash Ratio | 1.27 | 1.27 | 0.31 | 0.53 | 0.91 | 0.67 | 0.49 | 0.46 | 0.69 | 0.24 | 0.37 |
| Asset Turnover | — | 0.75 | 1.43 | 0.91 | 1.01 | 0.85 | 0.93 | 0.94 | 1.07 | 1.05 | 0.92 |
| Inventory Turnover | — | — | — | 5297.76 | 20.38 | 15.85 | 15.21 | 23.04 | 25.06 | 19.36 | 17.76 |
| Days Sales Outstanding | — | 8.41 | 6.70 | 6.13 | 8.52 | 8.84 | 9.15 | 7.88 | 6.57 | 6.68 | 8.62 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | 0.0% |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | 0.0% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 100.0% | 361.8% | — | — | — | 0.1% | 0.0% | 0.0% | 0.1% | 0.1% | 0.1% |
| FCF Yield | — | — | — | — | 0.2% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $10M | $80M | $77M | $70M | $71M | $70M | $70M | $70M | $68M | $66M |
Structural subscriber base erosion
According to current market data, WW trades at a P/S ratio of 0.23 and an EV/EBITDA of 4.10, suggesting that investors are heavily discounting the company's future earnings potential due to the ongoing contraction of its legacy subscription base and the high execution risk of its clinical pivot.
The extremely low valuation multiples indicate that the market is pricing in a high probability of terminal value impairment rather than a successful turnaround. Investors should monitor whether the forward EV/EBITDA of 4.78 signals a lack of confidence in the company's ability to achieve meaningful margin expansion through its new clinical service offerings.
Based on reported figures, WW's ROIC has trended into negative territory, reaching -3.6% in 2026Q1, which indicates that the company is currently destroying shareholder value as it struggles to generate returns on its invested capital while simultaneously funding a costly pivot toward a clinical weight-loss model.
The volatility in ROIC, which swung from 8.8% in 2024Q4 to -3.6% in 2026Q1, highlights the difficulty of maintaining operational efficiency during a fundamental business model shift. This trend suggests that the capital deployed into the clinical platform is not yet yielding the necessary returns to offset the decline in the core digital business.
As reported in recent financial statements, the company's asset turnover ratio has remained stagnant at approximately 0.18, reflecting a persistent inability to generate sufficient revenue from its existing asset base as the legacy subscription model faces significant headwinds and declining member engagement across its primary geographic segments.
The lack of improvement in asset turnover suggests that the company's infrastructure is underutilized, likely due to the shrinking subscriber base. Investors should be concerned that the current operational setup is not optimized for the lower-volume, higher-cost clinical model, potentially leading to further inefficiencies in the near term.
According to the most recent quarterly filings, WW maintains a debt-to-equity ratio of 1.76, which, when combined with a negative interest coverage ratio of -2.59, indicates that the company's ability to service its debt obligations is severely compromised under current operating conditions and requires immediate management attention.
The negative interest coverage ratio is a critical warning sign that the company's operating income is insufficient to cover its debt service requirements. This leverage profile significantly limits the company's ability to invest in growth initiatives and increases the risk of a liquidity crisis if the clinical pivot fails to gain traction.
As indicated by the anomalous 148.60% net margin, the P/E ratio is a fundamentally flawed metric for evaluating WW, as it is heavily distorted by non-recurring accounting events and debt restructuring gains that obscure the company's true, ongoing operational performance and cash-generating capacity.
Analysts should prioritize EV/EBITDA or FCF-based metrics to strip away the noise created by one-time accounting adjustments. Relying on P/E in this context may lead to a dangerous misinterpretation of the company's profitability, as it fails to account for the underlying structural decline in the core subscription business.
Includes 30+ ratios · 27 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying WW stock.
WW International, Inc.'s current P/E ratio is 0.2x. The historical average is 0.3x.
WW International, Inc.'s current EV/EBITDA is 4.1x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 49.4x.
WW International, Inc.'s return on equity (ROE) is 332.0%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is 209.9%.
Based on historical data, WW International, Inc. is trading at a P/E of 0.2x. Compare with industry peers and growth rates for a complete picture.
WW International, Inc. has 71.8% gross margin and 6.5% operating margin.
WW International, Inc.'s Debt/EBITDA ratio is 4.1x, indicating high leverage. A ratio above 4x may signal elevated financial risk.